CJC-1295 with DAC

CJC-1295 with DAC is a 30-amino-acid growth hormone releasing hormone (GHRH) analogue engineered to bind covalently to serum albumin, extending its half-life from minutes to about 5.8 to 8.1 days. Its human record is four studies in healthy volunteers, the longest lasting 49 days. Its only registered clinical trial, a 12-week phase 2 study in HIV-associated visceral obesity, was terminated in 2006 after a participant died, and has never reported results, twenty years later. A separately sold product, “CJC-1295 without DAC,” is a chemically different molecule with no human evidence at all.

Ask about CJC-1295

Research snapshot

CategoryCurrent information
Peptide categoryGHRH analogue (albumin-binding, long-acting)
Primary research interestSustained growth hormone/IGF-1 elevation (studied in healthy volunteers only)
Highest available evidenceTier 1 – published human pharmacology in healthy volunteers, no efficacy trial ever completed
Human research availableLimited – 4 studies, longest 49 days; one registered trial terminated and unreported
Development statusDiscontinued; no sponsor pursued it after the 2006 trial termination
Regulatory statusNot approved anywhere; nominated for FDA 503A compounding list, then withdrawn

Technical identity

Technical propertyInformation
Primary nameCJC-1295 (with DAC)
Alternative namesDAC:GRF, CJC-1295 DAC, long-acting GRF analogue
Peptide sequenceTetrasubstituted hGRF(1-29) with Lys30 bearing an N-epsilon-3-maleimidopropionamide, C-terminally amidated
Amino-acid length30 residues
Molecular formulaC165H269N47O46
Molecular weightAbout 3647.25 g/mol (derived from formula, not a quoted peer-reviewed value)
CAS Registry Number446262-90-4
PubChem CID91971820
UNII62RC32V9N7
Chemical modificationsMaleimidopropionyl group at position 30 (the “DAC”), four amino-acid substitutions relative to native GRF(1-29)
Peptide classGHRH analogue, long-acting (albumin-conjugating)
Primary biological targetPituitary GHRH receptor; DAC group binds cysteine-34 on serum albumin
Developer or originatorConjuChem
Development statusDiscontinued

What it is

CJC-1295 is a 30 amino acid analogue of growth hormone releasing hormone. It is the natural GHRH fragment 1 to 29 with four amino acid substitutions, plus a thirtieth residue carrying a maleimidopropionyl group. That group is the Drug Affinity Complex, or DAC, and it is the whole compound.

The DAC binds covalently to a free thiol on serum albumin, at cysteine 34. The peptide is then carried around attached to a protein that circulates for weeks, and its half-life in healthy adults is 5.8 to 8.1 days rather than minutes.

That is the point of the molecule. CJC-1295 was selected out of three candidates, alongside CJC-1288 and CJC-1293, precisely because its albumin conjugation lasted longest. Take the DAC away and it is not one of the three. It is what they started with.

A separate product is sold as CJC-1295 without DAC. It is a different molecule with a different formula and 279 daltons less mass, it has no human evidence of any kind, and it has its own entry on this site.

How it works

It binds the GHRH receptor on pituitary somatotrophs and raises growth hormone output, and through that, IGF-1. Nothing unusual there. What is unusual is the duration, and the duration raises the obvious question: does continuous stimulation flatten the natural pulses of growth hormone release?

One study has measured that, and the answer is no. In healthy men given a single injection of 60 or 90 micrograms per kilogram, twelve hours of twenty-minute sampling a week later showed trough growth hormone up 7.5 fold, mean growth hormone up 46 percent and IGF-1 up 45 percent, with pulse frequency and pulse magnitude unaltered (Ionescu 2006). The paper is titled for that finding.

Two details from it are worth carrying. There was no difference between the 60 and 90 microgram doses, and the IGF-1 rise did not correlate with any growth hormone measure.

Research evidence

Four human studies, all in healthy volunteers, all finished by 2009

The pharmacokinetic and pharmacodynamic work is Teichman 2006, reporting two randomised placebo-controlled ascending-dose trials of 28 and 49 days. A single injection raised growth hormone two to ten fold for at least six days and IGF-1 one and a half to three fold for nine to eleven days. After repeated doses, mean IGF-1 stayed above baseline for up to 28 days, and the authors described evidence of a cumulative effect. No serious adverse reactions were reported, and tolerability was described as relatively good particularly at 30 or 60 micrograms per kilogram, a qualifier that implies the higher doses in the ascending arm were tolerated less well.

Then the pulsatility study above, a serum proteomics study on eleven banked samples from it, and one terminated phase 2 trial. That is the complete human record, and the longest published exposure to CJC-1295 in a human being is 49 days.

Neither Teichman nor Ionescu has a trial registry record. Both ran before registration requirements applied, so this is an era effect rather than anything worse, but it means the two studies that generate every circulating figure for this compound have no pre-registered protocol and no independently recorded analysis plan.

The trial that ended the programme

NCT00267527 was a multicentre randomised double-blind placebo-controlled phase 2 trial of CJC-1295 in HIV-associated visceral obesity, 120 enrolled, twelve weeks of treatment. It started in December 2005 and it is recorded as terminated.

ConjuChem halted it on 17 July 2006 after the death of a participant at a site in Argentina, reported at the time as occurring hours after an eleventh injection. A 2026 review states the position now settled in the literature, that the trial was discontinued after an enrolled patient died from myocardial infarction. An account that the attending physician attributed the death to pre-existing asymptomatic coronary disease and considered it unrelated to treatment circulates widely, and could not be verified here against a primary source or a company filing.

Twenty years later that trial has no posted results and no publication. Its twelve-week treatment period would have been by far the longest human exposure on record and its safety dataset the most relevant to how the compound is actually used. It is unavailable.

The timing is worth noting. The termination sits between the publication of the pharmacokinetic paper in March 2006 and the pulsatility paper in December 2006, so the two studies that supply all the human data for CJC-1295 appeared around a programme that had already stopped.

The platform survived. The molecule did not.

ConjuChem albumin conjugation technology went on: its other clinical compound, an exendin conjugate for type 2 diabetes, completed two phase 3 trials under a successor company. Seven registered trials exist across the ConjuChem family and six of them concern that compound. CJC-1295 has one, and it was terminated. No other sponsor picked the molecule up, no phase 3 was ever registered, and no trial in growth hormone deficiency was ever registered despite that being where the preclinical rationale pointed.

What dosage information circulates?

Figures in this table summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
PK/PD, ascending doseSubcutaneous30–60 mcg/kg (per-dose values not fully published)Single/weekly/biweekly28–49 daysPublished human clinical trial
Pulsatility studyNot specified in source60 or 90 mcg/kgSingle doseN/APublished human clinical trial
Terminated phase 2 (HIV visceral obesity)Not specifiedLow and high dose (values never published)Not specified12 weeksRegistered but unpublished/terminated trial
General use (as sold)Subcutaneous1–2 mg per week1–2 injections/week8–16 weeks on, 4–6 offCommunity reported (bodybuilding-forum figures summarized in Dominikowski 2026, Front Endocrinol)

No dosing interval has ever been formally validated in humans – weekly dosing is inferred from the compound’s half-life, not a tested finding.

Potential benefits and research applications

Sustained growth hormone and IGF-1 elevation (the studied effect)

What is being investigated: whether long-acting GHRH stimulation raises GH/IGF-1 without disrupting normal pulsatile release. Evidence: Teichman 2006 (two ascending-dose PK/PD studies, 28 and 49 days) found single injections raised GH 2 to 10 fold for at least 6 days and IGF-1 1.5 to 3 fold for 9 to 11 days; repeated dosing kept mean IGF-1 above baseline for up to 28 days, described by the authors as a cumulative effect. Strength: this specific mechanistic effect is reasonably well demonstrated in healthy volunteers. Limitation: no efficacy endpoint (body composition, strength, any clinical outcome) has ever been tested in a completed human trial.

HIV-associated visceral obesity (the one clinical application attempted)

What is being investigated: whether CJC-1295 reduces visceral fat in this population, analogous to tesamorelin’s approved use. Evidence: one phase 2 trial (NCT00267527) was designed to test this, in 120 patients over 12 weeks, but it was terminated in 2006 after a participant death and has never reported results. Strength: none, the trial designed to answer this question never produced a usable answer.

Safety

There is no human safety data beyond 49 days by any route, and the one trial that would have produced twelve-week data reported nothing.

The mechanistic question specific to this compound is sustained elevation of IGF-1. Repeated dosing kept IGF-1 above baseline for up to 28 days in the Teichman work, and the consequence of holding IGF-1 up for months is not addressed anywhere in the human record for this molecule. The approved GHRH analogue on the market, tesamorelin, carries a label warning for increased risk of neoplasms, a contraindication in active malignancy and a requirement to monitor IGF-1 with a discontinuation threshold. No comparable framework exists here because there is no label.

Regulatory status

CJC-1295 is not an approved drug in any jurisdiction, in either form. It was nominated for the 503A bulk drug substances list and designated Category 2, the group of substances that may present significant safety risks in compounding. The nomination was later withdrawn, and it now appears in the withdrawn section of that page rather than the active Category 2 table. Withdrawal is not a clearance.

It was not among the substances considered at the July 2026 Pharmacy Compounding Advisory Committee meeting.

WADA names it directly. Section S2.2.4 of the prohibited list covers growth hormone releasing factors including GHRH and its analogues, and lists CJC-1293, CJC-1295, sermorelin and tesamorelin by name. Prohibited at all times, in and out of competition.

Frequently asked questions

What is CJC-1295 with DAC?

A long-acting GHRH analogue that binds to blood albumin, extending its activity from minutes to days.

How is it different from CJC-1295 without DAC?

The no-DAC version is a chemically different, lighter molecule with no albumin-binding chemistry and no human evidence at all.

Has it been studied in humans?

Yes, but only in healthy volunteers, in four small studies, for a maximum of 49 days.

What happened to its clinical trial?

Its one registered efficacy trial (HIV-associated visceral obesity) was terminated in 2006 after a participant death and has never reported results.

Is it FDA approved?

No. It was nominated for compounding-list inclusion and that nomination was withdrawn.

What dosage circulates online?

1 to 2 mg per week, subcutaneous, a weekly interval that’s mechanistically sensible given the half-life, though never formally validated.

Does it disrupt natural growth hormone pulses?

The one study that measured this found no, pulses continued normally during sustained stimulation.

Is it banned in sports?

Yes, named directly in WADA S2.2.4, prohibited at all times.

What remains unknown?

Everything beyond 49 days of use, what sustained IGF-1 elevation does over months, and whether the 2006 death was treatment-related.

Bottom line

CJC-1295 with DAC is a genuinely engineered long-acting GHRH analogue with real, specific pharmacology behind it, its albumin-binding mechanism works as designed, and the one study that tested whether it disrupts natural growth hormone pulsing found that it doesn’t. But the clinical program stopped cold in 2006: the only trial designed to test an actual health outcome was terminated after a participant died, and that trial’s data, which would be, twenty years on, still the most relevant safety information available on this molecule, has never been published. The complete human safety record tops out at 49 days.

Reported amounts and the evidence behind them: CJC-1295 dosage with DAC, without DAC and with ipamorelin.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
GeneralSubcutaneous1 to 2 mg per weekOne or two injections8 to 16 weeks on, 4 to 6 off
As part of a CJC and ipamorelin vialSubcutaneousVaries by sellerNot standardised8 to 12 weeks

This is the rare case where the circulating figures are lower than what was studied, and the interval is right for the molecule.

The convention is 1 to 2 milligrams a week, subcutaneous, in one or two injections. Weekly dosing makes sense for a compound with a 5.8 to 8.1 day half-life, and that rationale is correct here, unlike almost everything else on this site. The studied range was 30 to 60 micrograms per kilogram, which for a 70 kilogram adult is 2.1 to 4.2 milligrams a dose, so the market figure sits below it rather than above.

Two caveats keep that from being reassuring. The authors singled out 30 to 60 micrograms per kilogram as relatively well tolerated, which implies the higher doses in the same trial were tolerated less well, so the studied range is not a safety ceiling. And nothing in the literature validates a weekly interval as correct: it is inferred from the half-life, and the only study that varied frequency in an animal found daily dosing produced more than every 48 hours, which produced more than every 72.

The aggregate pattern reported here has been formally surveyed and published in a 2026 review, which searched commercial and forum material and tabulated it alongside the peer-reviewed regimens, treating it explicitly as behavioural material rather than evidence. That is the right framing and it travels with the figures.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Sources

  1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. Preclinical, three groups of one week old GHRH knockout mice given 2 micrograms of CJC-1295 at intervals of 24, 48 or 72 hours for 5 weeks against placebo treated and heterozygous controls. The only study that varied dosing frequency in a living animal: daily dosing restored normal body weight and length, while the same dose every 48 hours and every 72 hours left growth short of normalisation, with the 72 hour interval the weakest. PMID 16822960
  2. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. Human. The only human pharmacokinetic programme for CJC-1295, and it studied the DAC form, half life 5.8 to 8.1 days. Source of every sustained and prolonged claim attached to blends that do not contain it. PMID 16352683
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. Studied the DAC version. PMID 17018654
  4. Jette L, et al. Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. Defines CJC-1295 by the presence of the maleimidopropionyl group. PMID 15817669
  5. ConjuChem. CJC 1295 for 12 weeks in HIV-infected patients with HIV-associated visceral obesity. Phase 2, terminated, 120 enrolled, no results posted. NCT00267527
  6. Sackmann-Sala L, et al. Serum proteome changes in healthy men after CJC-1295 administration. Growth Horm IGF Res. 2009. PMID 19386527
  7. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026;54(1):223-9. Review, cited for the correction and not for support. Its abstract states that CJC-1295 combined with ipamorelin improved maximum tetanic tension in murine glucocorticoid-induced muscle loss. Full text was not retrievable. PMID 41476424
  8. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Front Endocrinol 2026;17:1822475. Review. States that the half life of CJC-1295 without DAC is not reported in human studies, that the combination with ipamorelin is largely driven by anecdotal rationale, and that no human trials of the combination exist. PMID 42395176
  9. US Food and Drug Administration. Ipamorelin acetate, 503B, listed 29 September 2023, citing immunogenicity risk and serious adverse events including death reported in the literature after intravenous administration. FDA Category 2
  10. World Anti-Doping Agency. Prohibited List, section S2.2.4, GHRH and its analogues, naming CJC-1293, CJC-1295, sermorelin and tesamorelin. Prohibited at all times. WADA S2.2.4

Live registry status

These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.

TrialPhaseStatusSponsorEnrolledPrimary completionRegistry updated
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
NCT00267527
Phase 2TerminatedConjuChem120Not statedOct 16, 2006

Open these in the trial tracker

Research area: Growth hormone axis.

Share thisFacebookXEmail